Capivasertib China PK Study

计划入组 16 人 · 首次发布于 2021 年 2 月 5 日

Rash & Diarrhea Prophylaxis With Capivasertib

计划入组 108 人 · 首次发布于 2026 年 2 月 23 日

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

计划入组 250 人 · 首次发布于 2025 年 12 月 15 日

Capivasertib(Truqap)

C₂₁H₂₅ClN₆O₂

Decentralized Clinical Trials Offer Hope for Rare Cancer Patients

Breakthrough Breast Cancer Drug Capivasertib Approved for NHS Use

NICE Approves Capivasertib-Fulvestrant Combination for Advanced Breast Cancer Treatment